Novartis announces global partnership with Amgen to develop and commercialize pioneering …

News Hour: Novartis announced today that it has entered into a global collaboration with Amgen to commercialize and develop pioneering neuroscience treatments. The companies will partner in the development and commercialization of a BACE inhibitor program in Alzheimer’s Disease. Novartis’ oral therapy CNP520 will be the lead molecule and further compounds from both company’s pre-clinical BACE inhibitor programs may be considered as follow-on molecules. The collaboration will also focus on new Amgen drugs in the migraine field, including phase III AMG 334 and phase I AMG 301. For the migraine program, Novartis will have global co-development rights and commercial rights outside the U.S., Canada, and Japan. “This Novartis collaboration with Amgen highlights our clear commitment to neuroscience and to bring multiple, new targeted therapies to patients living with Alzheimer’s disease…


Link to Full Article: Novartis announces global partnership with Amgen to develop and commercialize pioneering …